



Index

Note: Page numbers in **bold** refer to definitions.

A

absolute risk, **83**
absolute risk reduction, 44, **83**
access to care, 13–25
accountability, 67–73
ACS. *See* American Cancer Society
activism, 76–78, **83**
activists, **83**
acupuncture, 64, **83**
adenoid cystic carcinoma, **84–85**
adjuvant therapy, 40, **83**
advance directive, 20, 54, **83**
advanced breast cancer. *See also*
end-stage breast cancer;
metastatic breast cancer
needs in, 20
source of information on,
33, 105
treatments for, 31, 43, 53,
89, 97
advocates, breast cancer, 32,
58, 77–78, **83**
alien, qualified, **94–95**
aloe vera, 65
alternative medicine, 63–65, **83**
evidence-based information on,
source of, 99
American Bar Association,
Commission on Women in the
Profession, 73, 99
American Cancer Society (ACS),
64, 99
American Society of Clinical
Oncology (ASCO), 49, 100
anecdotal evidence, 39, **83–84**
anthracyclines, 61, **84**
appeals process, health insurance,
70, 71–72
appetite, loss of, as symptom of
cancer recurrence, 63
ASCO. *See* American Society of
Clinical Oncology
Avon Breast Cancer Crusade, 100
Avon Breast Care Fund, 18

B

behavioral medicine, 22, **84**
benefits, insurance, 14, **84**
benign tumor, **84**
biological therapy, 61, **84**
biopsy, 28, 51, **84**
sentinel lymph node, 40, **96**
biopsy report. *See* pathology report
blind study, 23, 41, **84**
Blue Cross and Blue Shield
Association, 40, 100
Board-certified doctors, 49
bone marrow, spread of
cancer to, 62
bone marrow transplants, high-dose
chemotherapy with, 71
bones, spread of cancer to, 29, 62
brain, spread of cancer to, 62
breast(s)
fake (prostheses), 21, 53, **86**
rebuilding (reconstruction), 21,
37, 38, 50, 53–55, **95**
removing (mastectomy), 21, 50,
51–52, 86, **91–92**
saving (breast-conserving
surgery), 38, 42, 51–52, **86**
Breast and Cervical Cancer
Treatment Act (2000), 15
breast cancer, **84**
activism, 76–78
diagnosis of. *See* diagnosis of
breast cancer
free/low-cost treatment of,
15–19, 100, 101, 102
needs of patients, 19–20
recurrence of. *See* recurrence
of breast cancer
remission of, 54, **96**
risk factors for, 69
screening for, 15–17, 100, 101
stages of, 28, 29
types of, 84–86
breast cancer clinical practice
guidelines, 20, 39–40

breast tissue slides, 28, **96**
preserving, 35, 36
breast-conserving surgery, 38,
51–52, **86**
breath, shortness of, as symptom
of cancer recurrence, 63

C

CAM, 63–65, **86**. *See also* alterna-
tive medicine; complementary
medicine cancer, **86**. *See also*
breast cancer
screenings for, 15–17, 100, 101
Cancer Care, 18, 100
Cancer Survival Toolbox
audiotapes, 50
carcinoma in situ, **85**
care. *See also* treatment
access to, 13–25
choice of. *See* choice of care
coordination of, 20, 22, 49, **87**
guidelines for, 20, 39–40
quality of. *See* quality of care
care centers. *See also* hospital(s)
choosing, 49
providing affordable services, 17
transportation to and from,
assistance with, 18–19
case series, 41, **86**
case-control studies, 41, 92
cell, 35, **86**
Centers for Disease Control and
Prevention (CDC)
contact information, 101
screenings offered by, 15–17,
101
Centers for Medicare and Medicaid
Services (CMS), 101
Centers for Medicare and Medicaid
Services (CMS), 14, 16
cervical cancer, 15, **86**
chemotherapy, 52, **86–87**
high-dose, with bone marrow
transplants, 71

Index

for node-positive breast cancer, 30
side effects of, 52, 61–62, 87
choice of care, 38, 47–55
 informed, taking time for, 7, 37
 responsibility for, 69
citation, 43, **87**
clinical practice guidelines, 20, 39–40
clinical trials, 20–21, 23–24, **87**
 controlled, 41, 42, **87**
 costs of, 25, 79
 finding, 24
 on Herceptin, 31–33, 53
 increasing access to, 79
 vs. observational study, 92
 randomized controlled, 41, 43, **95**
 reasons for joining, 23–24, 43
 restrictions for participation in, 37
 standards for judging, 24–25
CMS. *See* Centers for Medicare and Medicaid Services
cohort studies, 41, 92
colloid carcinoma, **85**
community standards, 39
comparison group. *See* control group
Compassion in Dying Federation, 54, 101
complaints, filing, 59
complementary medicine, 63–65, **87**
 evidence-based information on, source of, 99
complications, 61, **87**
comprehensive treatment plan, 61
computed tomography (CT) scan, 63, **87**
confidentiality. *See* privacy
control group, 23, 41, 42, **87**
controlled clinical trial, 41, 42, **87**
coordinated care, 20, 22, 49, **87**

cosmetic surgeon. *See* plastic surgeon
cost(s)
 of clinical trials, 25, 79
 help with, 15–19, 100
 of Medicare, 16
 out-of-pocket, **93**
coverage, 14, **88**. *See also* health insurance
 denial of, appealing, 71–72
 employer's control over, 70
 evidence-based, 69
 variations in, 70
CT scan, 63, **87**

D
DCIS. *See* ductal carcinoma in situ
diagnosis, **88**
diagnosis of breast cancer, 28
 and overtreatment, 32
 second opinion on, 34–35, 37–38, **96**
diagnostic services, 15, **88**
disability benefits, 15, 19
discrimination, genetic, 60, 78
disease characteristics, 30–33
doctor(s)
 choosing, 48–49
 clinical trials offered by, 20
 complaining about, 59
 errors by, 81, **92**
 kinds of, 38, 49
 making decisions with, 50–55
 questions to ask, 28–30, 37, 45
 recommending treatment, 30–33
 and research, knowledge of, 38–39
 respect in relations with, 57–65
 second opinion by, 34–35, 37–38, **96**
 specialists, 21, **96**
 tape recording of meetings with, 45, 48, 61
 team of, choosing, 22, 48
double-blind study, 23, **88**

Dr. Susan Love's Breast Book, 30, 32, 33, 34, 48, 51, 106
drug(s). *See* medicine
drug assistance programs, 18
duct, **88**
ductal carcinoma in situ (DCIS), 29, 32, **85**

E
elderly. *See* older women
employers
 genetic discrimination by, 60
 and health insurance, 14, 49, 70, 72, 90
end-of-life care, 54
end-stage breast cancer, 54, **88**
 vs. metastatic breast cancer, 33
epidemiology, 78
errors, medical, 81, **92**
estrogen, 52, **88**
estrogen receptor-negative breast cancer, 28, 31, **88**
estrogen receptor-positive breast cancer, 28, 31, 52, **88**
evidence, 39, **88**
 absence of, 43
 anecdotal, 39, **83–84**
 and choice of care, 37
 health insurance based on, 69
 and quality of care, 6
 treatment advice based on, 70
evidence-based medicine, 37, 38–39, 68, **88–89**
eye, spread of cancer to, 62

F
Family and Medicare Leave Act (FMLA), 19
family members, involving in care, 45, 50, 58, 73
federal laws
 about cancer treatment, 15, 21–22
 about clinical trials, 79
 about medical privacy, 60
 about patients' rights, 21–22

about time off from work, 19
feedback
 about health plan, 59
 about this Guide, 7
FindCancerExperts.com, 34, 101
FMLA. *See* Family and Medicare
 Leave Act
follow-up care, 62
foreigners. *See* qualified alien
free health care, 15–19, 100, 101,
 102
free legal help, 73
free medicine, 18, 106
free transportation, 18–19, 106
friends, involving in care, 45, 50,
 58, 73

G

genes, 35
genetic discrimination, 60, 78
genetic research, 35–36
genetic tests, 60, **89**
Georgetown University, Health
 Privacy Project, 45, 60, 102
getting health care, 13–25
getting to and from doctor, 18–19,
 106
guidelines for breast cancer care,
 20, 39–40

H

hair loss, chemotherapy and, 52, 61
health care. *See* care
health care coverage. *See* coverage
health care reform, advocacy for,
 78
health insurance, 14–15, **89**.
 See also coverage
 activism directed at, 77, 78
 appeals process, 70, 71–72
 choosing, 49
 and costs of clinical trials, 25
 evidence-based system of, 69
 exclusions under, 70–71
 filing complaint with, 59
 genetic discrimination by, 60
 giving feedback to, 59

premiums, 16, **90**
 and reconstructive surgery, 21
 and second opinion, 37
 variations in coverage, 70
health interventions, **90**
Health Legacy Partnership, 102
health outcomes, 78, 80, **89**
health plan, **89**. *See also* health
 insurance
Health Privacy Project, 45, 60, 102
help
 with health care costs, 15–19,
 100, 101
 with legal issues, 73
"Helping Hand Resource Guide,"
 18, 100
herbs, 65
Herceptin, 31, 53, **89**, 97
HER2/neu, 28, 31, 53, **89**
Hill-Burton Free Care Program,
 17–18, 102
hormonal therapy, 52, 61, **89**
hospice care, 54, **89**
hospital(s)
 choosing, 49
 pathology department at, 34
 providing affordable services, 17
 size of, and quality of care, 21
hospital insurance, Medicare, 16

I

implant, 53–55, **89**
in situ breast cancer, 29, 32, 85
infiltrating ductal carcinoma, 28, **85**
infiltrating lobular carcinoma, **85**
inflammatory breast cancer, **85–86**
informed consent, **90**
 in clinical trials, 24
Institute of Medicine (IOM), 81, 102
Institutional Review Board, 24, **90**
insurance. *See* health insurance
Internet, **90**
 clinical trial information on, 24
 free access to, 7
 judging information on, 44,
 107–108
 resources on, 7, 21

intervention, health, **90**
invasive breast cancer, 28, 29, 85
investigational group, 23, 41, 42, **90**
investigational treatments, 23, 25,
 43, **90**. *See also* clinical trials

J

job. *See* work
Joint Commission on Accreditation
 of Healthcare Organizations
 (JCAHO), 49, 103

L

law(s). *See* federal laws; states
lawyers, free advice from, 73
LCIS. *See* lobular carcinoma in situ
leukemia, **90**
liver, spread of cancer to, 29, 62
living will, 83
Lobby Day, 78
lobular carcinoma in situ (LCIS), 29,
 32, **85**
local recurrence, 62, **91**
local treatments, 51–52
Love, Dr. Susan, 30, 32, 33, 34, 48,
 51, 106
lumpectomy, 51–52, 86, **91**
lungs, spread of cancer to, 29, 62
lymph node(s), 30, **91**
 removing, 52
 sentinel, **96**
 spread of cancer to, 28, 29, 30,
 92
lymphedema, 21, **91**

M

magnetic resonance imaging (MRI),
 63, **91**
malignant tumor, **91**
mammogram (mammography), **91**
 in follow-up care, 62
 free/low-cost, 15–17, 77
mastectomy, 21, 50, 51–52, 86,
 91–92
Medicaid, 14, 17, **92**
 eligibility for, 15

Index

medical errors, 81, **92**
medical oncologist, 38, 49, **93**
medical practice, 38, **92**
medical records
 obtaining copies of, 45, 72
 privacy of, ensuring, 59–60
Medicare, 14, 16, **92**
 contact information, 103
 restrictions in coverage, 70–71
 Social Security Disability Insurance (SSDI) and, 15
medicine (medications)
 free, how to obtain, 18, 106
 health insurance for, 70–71
 for metastatic breast cancer, 89
Medline database, 43
medullary carcinoma, **86**
menopause, 69, **92**
metastasis (metastases), 62, **92**
metastatic breast cancer, 29, 54, **92**
 disability benefits with, 15, 19
 vs. end-stage breast cancer, 33
 source of information on, 33, 105
 symptoms and tests used to find, 63
 treatments for, 31, 43, 53, 89, 97
modified radical mastectomy, **91**
molecular profiles, 36
MRI. See magnetic resonance imaging

N

National Breast and Cervical Cancer Early Detection Program (NBCCEDP), 15–17, 101
National Breast Cancer Coalition Fund (NBCCF), 4, 115–116
 Advocacy Training Conference, 77–78
 becoming a member of, 76
 Board of Directors, 11
 contact information, 11, 99
 on costs of clinical trials, 25

field coordinators, 11, 15, 55
goals of, 115
Lobby Day, 78
Project LEAD®, 78
Quality Care Advisory Committee, 9, 10
Quality Care Initiative, 9
resources available from, 25, 60, 71
vision of quality care, 5–6
National Cancer Institute (NCI)
 breast cancer guidelines, 40
 contact information, 103
 database of clinical trials, 24
 sponsoring clinical trials, 25
 tips for judging Internet information, 107–108
National Center for Complementary and Alternative Medicine (NCCAM), 64, 103
National Coalition of Cancer Survivorship (NCCS), 50, 104
National Committee for Quality Assurance (NCQA), 49, 104
National Comprehensive Cancer Network (NCCN), 40, 104
National Conference of State Legislatures (NCSL), 22, 104
National Health Law Program, 81, 105
National Library of Medicine, 24, 105
National Partnership for Women and Families, 19, 105
needs of breast cancer patients, 19–20
nipple, reconstructing, 54–55
node-negative breast cancer, 30, **92**
node-positive breast cancer, 30, **92**

O

observational study, 41, **92**
occupational therapy, 16, **93**
older women
 health insurance for, 14, 16.

See also Medicare
 treatment recommendations for, 50
oncologist, 34, 38, 49, **93**. See also doctor(s)
outcomes, health, 78, 80, **89**
outcomes research, 79, **93**, 102
out-of-pocket costs, **93**
outpatient, 16, **93**
overtreatment, 32

P

pain, as symptom of cancer
 recurrence, 63
pain control, 19, 61, **93**
palliative care, 19, 33, **93**
pathologist, 28, 33, **93**
pathology report, 28, 33–34, **93**
 second opinion on, 34–35
patient navigators, 22
Patient Travel organization, 18, 106
Patient-Centered Guides, 105
patients' rights, 21–22
 to privacy, 59–60
 to second opinion, 96
paying for health care, 14–19
peer review, 41, **93**
Pharmaceutical Researchers and Manufacturers of America (PhRMA), 18, 106
physical therapy, 16, **94**
Physician Data Query (PDQ), 40
plastic surgeon, 21, 37, 38, 53–55, **94**
precancerous condition, 29, 32, **94**
premium, insurance, 16, **90**
prevention, vs. risk reduction, 45
primary breast cancer, **94**
primary care doctor, **94**
primary tumor, **94**
privacy
 of medical records, 59–60
 sources of information on, 45
progesterone, 52, **94**
progesterone receptor-negative

breast cancer, 28, 31, **94**
progesterone receptor-positive
breast cancer, 28, 31, 52, **94**
prognosis, 72, **94**
Project LEAD®, 78
prostheses, breast, 21, 53, **86**

Q

qualified alien, **94–95**
quality of care, 5–6
evidence and, 6
improving, 75–81
measures of, 80–81
problems with, 4
quality of life, **95**
choice of treatment and, 44, 50,
61

R

radiation, 52, 61, **95**
after lumpectomy, 51
for node-positive breast cancer,
30
radiation oncologist, 38, 49, **93**
radical mastectomy, **91–92**
radiologist, **95**
randomization, 23, 43, **95**
randomized controlled clinical trial,
41, 43, **95**
receptors, 31, **95**
reconstructive surgery, 21, 37, 38,
50, 53–55, **95**
records. *See* medical records
recurrence of breast cancer, 62,
63, **96**
local, 62, **91**
regional, 62
relative risk, **96**
relative risk reduction, 44, **96**
reliability of research, 42, **96**
remission, 54, **96**
research. *See also* clinical trials
advocacy for, 78
doctors and, 38–39
genetic, 35–36
outcomes, 79, **93**, 102

reliability of, 42, **96**
validity of, 42, **97**
researchers, sharing health care
information with, 35
respect, in patient-doctor relations,
57–65
results
of health care, measuring, 79
of research, finding, 43
of tests, getting copies of, 45, 72
retirement option, 19
rights of patients, 21–22
to privacy, 59–60
to second opinion, 96
risk, **83**
risk factors for breast cancer, 69
risk reduction, 44
absolute, 44, **83**
vs. prevention, 45
vs. quality of life, 61
relative, 44, **96**

S

Saint John's Wort, 64
screenings, cancer, 15–17, 100,
101
second opinion, 34–35, 37–38, **96**
senior citizens. *See* older women
sentinel lymph node biopsy, 40, **96**
settlement, **96**
slides, breast tissue, 28, **96**
preserving, 35, 36
Social Security Administration, 16,
106
Social Security Disability Insurance
(SSDI), 15, 19
specialists, 21, **96**.
See also doctor(s)
specific disease characteristics,
30–33, **96**
spinal cord, spread of cancer to, 62
standard of care, 20, 40, 68, **96–97**
states
and breast cancer laws, 22
and clinical trial costs, 79
and health care programs, 17

and Medicaid, 14, 17
and medical privacy laws, 60
screening services offered by,
15, 101
statistical methods, 41
statistical significance, **97**
statistical techniques/methods, **97**
stomach, upset
alternative treatment for, 64
chemotherapy and, 52
studies. *See also* research
Medline database of, 43
ranking of, 41
types of, 23, 41
supplements, 65
surgeon(s), 37, 38, 49.
See also doctor(s)
experience of, checking, 21
plastic, 21, 37, 38, 53–55, **94**
surgery
breast-conserving, 38, 51–52,
86
reconstructive, 21, 37, 38, 50,
53–55, **95**
tissue flap, 53–55, **97**
surgical oncologist, 38, **93**
SusanLoveMD.com, 106
systemic treatments, 52, **97**

T

Tamoxifen, 31, 52, 70–71, 89, **97**
tape recording of meetings with
doctor, 45, 48, 61
targeted treatments, 53–54, **97**
tele-medicine, 21
time
patients', respect for, 58–59
taking, for informed choices, 7,
37
tissue flap surgery, 53–55, **97**
transportation, assistance with,
18–19, 106
treatment. *See also* care
for advanced breast cancer, 31,
43, 53, 89, 97
alternative, 63–65, **83**

Index

choice of, 38, 50–55, 61–62
complementary, 63–65, **87**
comprehensive plan for, 61
disease characteristics and,
30–33
evaluation of, 65
free/low-cost, 15–19, 100,
101, 102
hormonal, 61, **89**
investigational, 23, 25, 43, **90**
local, 51–52
of precancerous condition, 32
questions to ask about, 45
risks and benefits of, asking
about, 45
systemic, 52, **97**
targeted, 53–54, **97**
treatment second opinion, 34, 37
tubular carcinoma, **86**
tumor
 benign, **84**
 malignant, **91**
 primary, **94**
 size of, 31

U

uncontrolled studies, 41, 42, 86
unpaid leave, 19

V

validity of research, 42, **97**
vitamins, 65

W

Web site, **97**. *See also* Internet
weight changes, as symptom of
 cancer recurrence, 63
will, living, 83
The Women's Health and Cancer
 Rights Act (1998), 21
work
 health insurance through, 14,
 49, 70, 72, 90
 time off from, 19
World Wide Web. *See* Internet

Y

Y-ME National Breast Cancer
 Organization, 30, 34, 106